Last reviewed · How we verify
Nazasetron (AZASETRON)
Nazasetron (generic name: AZASETRON) is a azasetron drug. It is currently in Phase 2 development.
Nazasetron works by binding to the 5-hydroxytryptamine receptor 3A, blocking its action and reducing symptoms.
Nazasetron, also known as AZASETRON, is a small molecule drug that targets the 5-hydroxytryptamine receptor 3A. It belongs to the azasetron class and is used to treat certain conditions. However, its commercial status and approved indications are unknown. Further research is needed to determine its safety profile and potential side effects. As a result, it is not currently available in the market.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AZASETRON |
|---|---|
| Drug class | azasetron |
| Target | 5-hydroxytryptamine receptor 3A |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body has a system of locks and keys. The 5-hydroxytryptamine receptor 3A is like a lock, and serotonin is the key. Nazasetron is a key that blocks the lock, preventing serotonin from triggering certain responses in the body.
Approved indications
Common side effects
Key clinical trials
- SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease (PHASE2)
- Evaluation of the Presence of SENS-401 in the Perilymph (PHASE2)
- Esketamine and Butorphanol for Post-Lobectomy Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nazasetron CI brief — competitive landscape report
- Nazasetron updates RSS · CI watch RSS
Frequently asked questions about Nazasetron
What is Nazasetron?
How does Nazasetron work?
What is the generic name of Nazasetron?
What drug class is Nazasetron in?
What development phase is Nazasetron in?
What does Nazasetron target?
Related
- Drug class: All azasetron drugs
- Target: All drugs targeting 5-hydroxytryptamine receptor 3A
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing